Twist Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Twist Bioscience (TWST).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

10Buy

3Hold

2Sell

Consensus RatingBuy# Analysts15Avg. Consensus PT$99Upside to Avg. PT-38.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	Jefferies	Matthew Stanton	Initiate	Hold	$150
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$112→$215
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$107→$212
Sep 29, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$160→$190
Sep 18, 2026	BWS Financial	Hamed Khorsand	Maintained	Sell	$45
Sep 17, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$120→$160
Sep 9, 2026	BWS Financial	Hamed Khorsand	Initiate	Sell	$45
Sep 9, 2026	UBS	Doug Schenkel	Initiate	Neutral	$144
Aug 5, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$85→$115
Aug 4, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$113→$115
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$90→$120
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	Downgrade	Outperform→In-Line	$66→$102
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$60→$107
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$65→$95
Jun 15, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$68→$89
Jun 15, 2026	Canaccord Genuity	Kyle Mikson	Initiate	Buy	$90
Jun 11, 2026	Piper Sandler	David Westenberg	Initiate	Overweight	$85
May 5, 2026	Leerink Partners	Puneet Souda	Upgrade	Market Perform→Outperform	$70
May 5, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$55→$65
May 5, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$55→$60

More with Benzinga EdgeGet Access

Analyst Ratings News

This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Overweight GNRC ($303), Buy ENTG ($200) and VYLR ($87), Neutral SPOT ($540).

Avi Kapoor

PRO
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

Jefferies analyst Matthew Stanton initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Hold rating and announces Price Target of $150.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $112 to $215.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $107 to $212.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

Leerink Partners analyst Puneet Souda maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $160 to $190.

Benzinga Newsdesk

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.

Benzinga Newsdesk

Twist Bioscience Corp

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

PRO
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

People Also Watch

People Also Watch

Twist Bioscience Corp

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROJefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

PROBarclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

PROGuggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

PROLeerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

PROBWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

People Also Watch

People Also Watch

PRO
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

PRO
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45